Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Ventures (TVI) has granted a fund to Redwood Bioscience to develop its site specific protein modification technology to enhance antibody-drug conjugates and peptide therapeutics.
Subscribe to our email newsletter
Redwood’s technology was launched based on aldehyde tagging which functions as a chemical site on the surface of a protein that can be selectively modified through aldehyde specific chemistry.
Redwood Bioscience co-founder, president and CSO David Rabuka said similar to the advancement of small molecule generation and optimization with combinatorial chemistry and rational drug design, Redwood’s technology has the potential to advance the field of conjugate therapeutics.
"By providing control over cargo location, number and orientation on a protein, the company’s technology enables the generation of chemically modified protein libraries for optimal conjugate selection," Rabuka said.
Redwood CEO Karen Boezi said Takeda’s investment not only provides capital but access to industry professionals at TVI who are already supportive in the company’s development efforts.